157 related articles for article (PubMed ID: 20449627)
1. Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.
Soto E; Keizer RJ; Trocóniz IF; Huitema AD; Beijnen JH; Schellens JH; Wanders J; Cendrós JM; Obach R; Peraire C; Friberg LE; Karlsson MO
Invest New Drugs; 2011 Oct; 29(5):984-95. PubMed ID: 20449627
[TBL] [Abstract][Full Text] [Related]
2. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
[TBL] [Abstract][Full Text] [Related]
3. PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.
Zandvliet AS; Siegel-Lakhai WS; Beijnen JH; Copalu W; Etienne-Grimaldi MC; Milano G; Schellens JH; Huitema AD
Clin Pharmacol Ther; 2008 Jun; 83(6):829-39. PubMed ID: 17851564
[TBL] [Abstract][Full Text] [Related]
4. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
van Kesteren C; Zandvliet AS; Karlsson MO; Mathôt RA; Punt CJ; Armand JP; Raymond E; Huitema AD; Dittrich C; Dumez H; Roché HH; Droz JP; Ravic M; Yule SM; Wanders J; Beijnen JH; Fumoleau P; Schellens JH
Invest New Drugs; 2005 Jun; 23(3):225-34. PubMed ID: 15868378
[TBL] [Abstract][Full Text] [Related]
5. Semimechanistic cell-cycle type-based pharmacokinetic/pharmacodynamic model of chemotherapy-induced neutropenic effects of diflomotecan under different dosing schedules.
Mangas-Sanjuan V; Buil-Bruna N; Garrido MJ; Soto E; Trocóniz IF
J Pharmacol Exp Ther; 2015 Jul; 354(1):55-64. PubMed ID: 25948593
[TBL] [Abstract][Full Text] [Related]
6. The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
Hansson EK; Friberg LE
Cancer Chemother Pharmacol; 2012 Apr; 69(4):881-90. PubMed ID: 22057837
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic-pharmacodynamic modeling and model-based prediction of docetaxel-induced neutropenia in Japanese patients with non-small cell lung cancer.
Fukae M; Shiraishi Y; Hirota T; Sasaki Y; Yamahashi M; Takayama K; Nakanishi Y; Ieiri I
Cancer Chemother Pharmacol; 2016 Nov; 78(5):1013-1023. PubMed ID: 27709284
[TBL] [Abstract][Full Text] [Related]
8. Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.
Zandvliet AS; Schellens JH; Copalu W; Beijnen JH; Huitema AD
J Pharmacokinet Pharmacodyn; 2009 Feb; 36(1):39-62. PubMed ID: 19199010
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Sun W; O'Dwyer PJ; Finn RS; Ruiz-Garcia A; Shapiro GI; Schwartz GK; DeMichele A; Wang D
J Clin Pharmacol; 2017 Sep; 57(9):1159-1173. PubMed ID: 28419480
[TBL] [Abstract][Full Text] [Related]
10. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis) induced neutropenia.
Hing J; Perez-Ruixo JJ; Stuyckens K; Soto-Matos A; Lopez-Lazaro L; Zannikos P
Clin Pharmacol Ther; 2008 Jan; 83(1):130-43. PubMed ID: 17597713
[TBL] [Abstract][Full Text] [Related]
11. A multi-centre dose-escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy.
Graham JS; Falk S; Samuel LM; Cendros JM; Evans TR
Cancer Chemother Pharmacol; 2009 Apr; 63(5):945-52. PubMed ID: 18654747
[TBL] [Abstract][Full Text] [Related]
12. Semimechanistic Bone Marrow Exhaustion Pharmacokinetic/Pharmacodynamic Model for Chemotherapy-Induced Cumulative Neutropenia.
Henrich A; Joerger M; Kraff S; Jaehde U; Huisinga W; Kloft C; Parra-Guillen ZP
J Pharmacol Exp Ther; 2017 Aug; 362(2):347-358. PubMed ID: 28600397
[TBL] [Abstract][Full Text] [Related]
13. Comparison of different semi-mechanistic models for chemotherapy-related neutropenia: application to BI 2536 a Plk-1 inhibitor.
Soto E; Staab A; Doege C; Freiwald M; Munzert G; Trocóniz IF
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1517-27. PubMed ID: 21516508
[TBL] [Abstract][Full Text] [Related]
14. Mechanistic models for myelosuppression.
Friberg LE; Karlsson MO
Invest New Drugs; 2003 May; 21(2):183-94. PubMed ID: 12889739
[TBL] [Abstract][Full Text] [Related]
15. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.
Latz JE; Karlsson MO; Rusthoven JJ; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):412-26. PubMed ID: 16322990
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetic-pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitor.
Saito T; Iida S; Abe M; Jones K; Kawanishi T; Twelves C
J Pharm Pharmacol; 2013 Aug; 65(8):1168-78. PubMed ID: 23837584
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy.
Latz JE; Rusthoven JJ; Karlsson MO; Ghosh A; Johnson RD
Cancer Chemother Pharmacol; 2006 Apr; 57(4):427-35. PubMed ID: 16322992
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic analysis of neutropenia following nab-paclitaxel administration in Japanese patients with metastatic solid cancer.
Tsushima T; Kasai H; Tanigawara Y
Cancer Chemother Pharmacol; 2020 Oct; 86(4):487-495. PubMed ID: 32930844
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic-pharmacodynamic analysis of neutropenia in cancer patients receiving PM00104 (Zalypsis(®)).
González-Sales M; Valenzuela B; Pérez-Ruixo C; Fernández Teruel C; Miguel-Lillo B; Soto-Matos A; Pérez-Ruixo JJ
Clin Pharmacokinet; 2012 Nov; 51(11):751-64. PubMed ID: 23055348
[TBL] [Abstract][Full Text] [Related]
20. Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical development.
Soto E; Staab A; Tillmann C; Trommeshauser D; Fritsch H; Munzert G; Trocóniz IF
Cancer Chemother Pharmacol; 2010 Sep; 66(4):785-95. PubMed ID: 20062994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
